GSK3745417

DRUG2 trials

Sponsors

GlaxoSmithKline

Conditions

Leukemia, Myeloid, AcuteNeoplasms

Phase 1

A First Time in Human (FTIH) Study of GSK3745417 Administered to Participants With Advanced Solid Tumors

TerminatedNCT03843359

GlaxoSmithKlineNeoplasms

Start: 2019-03-12End: 2026-01-09Updated: 2026-08-03

A Phase 1, Open Label Study of Intravenous GSK3745417 to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Determine RP2D & Schedule in Participants With Relapsed or Refractory Myeloid Malignancies Including AML and HR MDS

TerminatedNCT05424380

GlaxoSmithKlineLeukemia, Myeloid, Acute

Start: 2022-09-20End: 2024-03-04Updated: 2025-03-25

Related Papers

Direct, Potent, and TP53-Independent Activity of Sting Agonists Against Acute Myeloid Leukaemia Enhances Venetoclax Efficacy <i>In Vivo</i>

Blood2023-11-021 citations

PB1887: STING AGONIST FOR THE TREATMENT OF RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA AND HIGH-RISK MYELODYSPLASTIC SYNDROME: A FIRST-IN-CLINIC PHASE 1 STUDY OF GSK3745417

HemaSphere2023-08-012 citations

Abstract CT124: A first-in-clinic phase 1 study of GSK3745417 STING agonist in relapsed/refractory acute myeloid leukemia and high-risk myelodysplastic syndrome

Cancer Research2023-04-1410 citations